XML 56 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (USD $)
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 33,719,796 $ 5,646,021
Short-term investments 18,905,608 8,034,001
Accounts receivable 3,301,563 830,433
Accounts receivable from affiliated entity 0 36,234
Prepaid expenses and other current assets 637,433 471,328
Prepaid expenses and other current assets from affiliated entity 2,057,350 887,167
Deferred tax asset 61,839 62,728
Total current assets 58,683,589 15,967,912
Restricted cash 100,762 100,410
Fixed assets, net 2,886,545 363,021
Investment in affiliated entity 9,664,587 10,703,332
Intangible assets, net 5,718,778 7,489,315
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 717,500 267,200
Other assets 402,075 134,193
Total assets 88,287,207 45,138,754
Current liabilities:    
Accounts payable and accrued expenses 5,444,508 3,181,574
Accounts payable and accrued expenses due to affiliated entity 522,255 187,275
Accrued clinical trial expenses 1,446,180 1,405,896
Common stock warrants 19,540,583 2,859,899
Deferred revenue 1,624,388 353,391
Deferred revenue from affiliated entity 388,542 388,542
Total current liabilities 28,966,456 8,376,577
Deferred revenue, net of current portion 1,997,333 88,609
Deferred revenue from affiliated entity, net of current portion 1,211,694 1,586,694
Deferred rent 3,013,263 65,076
Deferred tax liabilities 195,778 164,393
Total liabilities 35,384,524 10,281,349
Commitments and contingencies      
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 26 at both December 31, 2013 and December 31, 2012 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2013 and 300,000,000 at December 31, 2012, issued and outstanding: 210,304,821 at December 31, 2013 and 144,313,005 at December 31, 2012 210,305 144,313
Additional paid-in capital 348,109,661 263,897,116
Accumulated deficit (295,788,577) (229,760,129)
Accumulated other comprehensive (loss) income (76,365) 73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 52,455,024 34,354,662
Non-controlling interest 447,659 502,743
Total stockholders' equity 52,902,683 34,857,405
Total liabilities and stockholders’ equity $ 88,287,207 $ 45,138,754
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.